Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway

Prostate. 2008 Sep 15;68(13):1443-9. doi: 10.1002/pros.20810.

Abstract

Background: Zinc accumulation diminishes early in the course of prostate malignancy and continues to decline during progression toward hormone-independent growth. In contrast, constitutive levels of NF-kappaB activity increase during progression of prostate cells toward greater tumorigenic potential. We have reported previously that physiological levels of zinc suppress NF-kappaB activity in prostate cancer cells and reduce expression of pro-angiogenic and pro-metastatic cytokines VEGF, IL-6, IL-8, and MMP-9 associated with negative prognostic features in prostate cancer.

Methods: Intracellular zinc levels were examined by atomic absorption spectroscopy. NF-kappaB activity was examined by TransAm and Luciferase reporter assays, and Western blot analysis of p50 nuclear translocation. VEGF, IL-6 and IL-8 levels were assessed by ELISA.

Results: Selective zinc deficiency induced by the membrane-permeable zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN) increases activation of NF-kappaB and up-regulates expression of the NF-kappaB controlled pro-angiogenic and pro-metastatic cytokines VEGF, IL-6 and IL-8 in androgen-independent PC-3 and DU-145 prostate cancer cells. Pre-incubation with I kappaB alpha dominant mutant adenovirus efficiently blocks expression of these cytokines in zinc deficient cells indicating that the observed effects are NF-kappaB dependent.

Conclusions: Our findings suggest that zinc deficiency may contribute to the tumor progression via augmented expression of the NF-kappaB-dependent pro-tumorigenic cytokines.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology
  • Cation Transport Proteins / genetics
  • Cell Line, Tumor
  • Chelating Agents / pharmacology
  • Ethylenediamines / pharmacology
  • Humans
  • Interleukin-6 / metabolism*
  • Interleukin-8 / metabolism*
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • NF-kappa B / metabolism*
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Signal Transduction / physiology
  • Transfection
  • Vascular Endothelial Growth Factor A / metabolism*
  • Zinc / metabolism*

Substances

  • Cation Transport Proteins
  • Chelating Agents
  • Ethylenediamines
  • Interleukin-6
  • Interleukin-8
  • NF-kappa B
  • SLC39A1 protein, human
  • Vascular Endothelial Growth Factor A
  • Matrix Metalloproteinase 9
  • Zinc
  • N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine